← Back to Search

Amino Acid

L-Serine for Lou Gehrig's Disease (ALS Trial)

Phase 2

Waitlist Available

Led By Elijah W Stommel, MD,PHD

Research Sponsored by Elijah W. Stommel

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 1 year

Awards & highlights

ALS Trial Summary

This trial is testing a new ALS treatment to see if it is safe and effective.

Eligible Conditions

Lou Gehrig's Disease

ALS Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Dose tolerability based on subject reporting

Secondary outcome measures

Efficacy based on ALS Functional Rating Scale - Revised (ALSFRS-R)

Efficacy based on neurological exam

Efficacy based on pulmonary forced vital capacity

ALS Trial Design

1Treatment groups

Experimental Treatment

Group I: L-SerineExperimental Treatment1 Intervention

L-Serine 15 grams orally twice a day as tolerated for 6 months

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Elijah W. StommelLead Sponsor

Brain Chemistry Labs, Institute for EthnomedicineUNKNOWN

1 Previous Clinical Trials

40 Total Patients Enrolled

Elijah W Stommel, MD,PHDPrincipal InvestigatorDartmouth-Htichcock Medical Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What maladies has L-Serine been found to alleviate?

"L-Serine has proven to be an efficacious therapy when treating iron deficiency and supplementing amino acid deficiencies."

Answered by AI

Has the FDA sanctioned L-Serine for therapeutic applications?

"Our team at Power has evaluated the safety of L-Serine and assigned it a score of 2 due to evidence from Phase 2 trials that suggest its harmlessness, yet lack any proof for effectiveness."

Answered by AI

What is the current cohort size of this clinical trial?

"Affirmative. The information on clinicaltrials.gov suggests that enrollment for this trial is ongoing - the study was established on October 24th 2018 and the details were last updated on February 22nd 2022. At present, they are seeking 50 participants from one location."

Answered by AI

Could you tell me if this clinical experiment is currently seeking participants?

"Affirmative. Data from clinicaltrials.gov shows that this medical trial, which commenced on October 24th 2018, is actively seeking participants for enrolment. 50 patients are needed to be recruited from one location."

Answered by AI

Has L-Serine been investigated in prior empirical investigations?

"Currently, 4 clinical trials exploring the effects of L-Serine are ongoing with none in their final stages. While Lebanon, New hampshire has a concentration of these studies, there exists another 5 sites where research is taking place."

Answered by AI

Recent research and studies

Journal of Clinical InvestigationJournal

Oral L-serine Supplementation Reduces Production of Neurotoxic Deoxysphingolipids in Mice and Humans with Hereditary Sensory Autonomic Neuropathy Type 1

Garofalo, Kevin, Anke Penno, Brian P. Schmidt, Ho-Joon Lee, Matthew P. Frosch, Arnold von Eckardstein, Robert H. Brown, Thorsten Hornemann, and Florian S. Eichler. 2011. “Oral L-serine Supplementation Reduces Production of Neurotoxic Deoxysphingolipids in Mice and Humans with Hereditary Sensory Autonomic Neuropathy Type 1”. Journal of Clinical Investigation. American Society for Clinical Investigation. doi:10.1172/jci57549.

Journal of Neurology, Neurosurgery & PsychiatryJournal

The Syndrome of Cognitive Impairment in Amyotrophic Lateral Sclerosis: A Population-based Study

Phukan, Julie, Marwa Elamin, Peter Bede, Norah Jordan, Laura Gallagher, Susan Byrne, Catherine Lynch, Niall Pender, and Orla Hardiman. 2011. “The Syndrome of Cognitive Impairment in Amyotrophic Lateral Sclerosis: A Population-based Study”. Journal of Neurology, Neurosurgery & Psychiatry. BMJ. doi:10.1136/jnnp-2011-300188.

Journal of Biopharmaceutical StatisticsJournal

Comments on the Draft Guidance on “adaptive Design Clinical Trials for Drugs and Biologics

Brannath, Werner, Hans Ulrich Burger, Ekkehard Glimm, Nigel Stallard, Marc Vandemeulebroecke, and Gernot Wassmer. 2010. “Comments on the Draft Guidance on “adaptive Design Clinical Trials for Drugs and Biologics” of the U.S. Food and Drug Administration”. Journal of Biopharmaceutical Statistics. Informa UK Limited. doi:10.1080/10543406.2010.514453.

NeurologyJournal